Loading
JS111 is an experimental small-molecule drug from Suzhou Junjing BioSciences in phase 2 trials for non-small-cell lung cancer, aimed at EGFR and MET.
JS111 is a small-molecule drug developed by Suzhou Junjing BioSciences. Its targets are EGFR and MET (the sponsor names EGFR). The sponsor states: Oral EGFR tyrosine kinase inhibitor (capsule) targeting EGFR exon 19 deletion and L858R sensitising mutations in NSCLC, dosed once daily; an active metabolite (M546b) is also tracked. ClinicalTrials.gov describes the intervention as: In Phase I, approximately 3-12 subjects will be enrolled in each dose group (160 mg QD or 240 mg QD) and receive oral JS111 capsules once daily until any treatment discontinuation criteria are met. After all subjects have completed at least. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in non-small-cell lung cancer. The largest, NCT06940401, plans to enrol 44 participants (actual) with primary completion expected 2028-07-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
1.JS111 slips into a pocket on EGFR.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"JS111" OR ABSTRACT:"JS111") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about JS111, not a curated reading list.
Shares MET, EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares MET, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares MET, EGFR, Non-small-cell lung cancer and the tag pipeline.